TAKEDA PHARMACEUTIC

Takeda’s latest SEC filing shows a senior officer increasing his stake to 191,000 shares, confirming continued executive ownership and stability.

Takeda’s FDA priority review of oral TYK2 inhibitor Zasocitinib promises rapid, durable plaque psoriasis relief—especially for scalp and nail lesions—with a superior safety profile that could command a premium price.

Takeda’s Mimrylo (rusfertide) gains FDA approval, a first hepcidin‑mimetic therapy that cuts iron, lowers hemoglobin, and reduces phlebotomy in polycythemia vera patients.

Takeda’s new strategy blends AI‑driven drug discovery, lean corporate restructuring, proactive regulatory dialogue, and disciplined finance to boost innovation, speed and shareholder value.

Takeda Q1 2026: revenue up 5.4% despite net‑profit dip, driven by yen gain and flagship drugs, while operating margin grows and pipeline strength keeps growth prospects strong.

Takeda raises ¥1.2 trillion to fuel a high‑investment R&D pipeline across oncology, autoimmune, rare disease and neurology, boosting shareholder confidence and market share.